Byun JM et al. Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1. ASH 2025;Abstract 5835.
Hartley-Brown MA et al. Mezigdomide-A novel cereblon E3 ligase modulator under investigation in relapsed/refractory multiple myeloma. Cancers (Basel) 2024 Mar 15;16(6):1166. Abstract
Korst CLBM et al. Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): A multicentre, single arm, phase 2 trial. Lancet Haematol 2026;13(1):e30-40. Abstract
Landgren O et al. A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The ReKinDLE study. ASH 2025;Abstract 251.
Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract
Merz L et al. The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial. ASH 2025;Abstract 1033.
Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: STOMP phase 1 results. ASH 2025;Abstract 4010.
Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070.
Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372.
Richardson PG et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial. ASH 2023;Abstract 1013.
Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract
Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract
Suvannasankha A et al. Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial. ASH 2025;Abstract 100.
van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101.
van de Donk NWCJ et al. The role of CELMoD agents in multiple myeloma. Onco Targets Ther 2025;18:921-33. Abstract
White D et al. Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. ASCO 2025;Abstract 7532.